Stockreport

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF Atea Pharmaceuticals, Inc. Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Ex [Read more]